Among patients who received venetoclax–rituximab for R/R CLL in the MURANO study, high genomic complexity was associated with inferior PFS, and lower uMRD rates were observed among patients with disease harboring TP53, NOTCH1, BRAF and BIRC3 mutations [64]. The gene discussed is NOTCH1; the disease is B-cell chronic lymphocytic leukemia.